Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In healthy subjects, the incretin effect during an oral glucose tolerance test increases with the size of glucose load, resulting in similar glucose excursions independently of the glucose loads. Whether patients with type 2 diabetes mellitus (T2DM) are able to regulate their incretin effect is unknown. RESEARCH DESIGN AND METHODS: Incretin effect was measured over 6 d by means of three 4-h oral glucose tolerance test with increasing glucose loads (25, 75, and 125 g) and three corresponding isoglycemic iv glucose infusions in eight patients with T2DM [fasting plasma glucose, mean 7.7 (range 7.0-8.9) mM; glycosylated hemoglobin, 7.0% (6.2-8.4%)] and eight matched healthy control subjects [fasting plasma glucose, 5.3 (4.8-5.7) mM; glycosylated hemoglobin, 5.4% (5.0-5.7%)]. RESULTS: Patients with T2DM exhibited higher peak plasma glucose in response to increasing oral glucose loads, whereas no differences in peak plasma glucose values among control subjects were observed. The incretin effect was significantly (P < 0.003) lower in patients with T2DM (0 ± 7, 11 ± 9, and 36 ± 5%) as compared with control subjects (36 ± 5, 53 ± 6, and 65 ± 6%). Equal and progressively delayed gastric emptying due to the increasing loads was found in both groups. Incretin hormone responses were similar. CONCLUSIONS: Up-regulation of the incretin effect in response to increasing oral glucose loads seems to be crucial for controlling glucose excursions in healthy subjects. Patients with T2DM are characterized by an impaired capability to regulate their incretin effect, which may contribute to the exaggerated glucose excursions after oral ingestion of glucose in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [17]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 2×
“The incretin effect is gauged by comparing insulin responses after oral ingestion of glucose and isoglycemic iv glucose infusion (IIGI), respectively (6).”
BackgroundMethodTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 6×
“(7) and us among healthy subjects are likely to result from deceleration of gastric emptying in response to the larger oral glucose loads as indicated by the acetaminophen results of the present study.”
BackgroundResultInfluentialDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Research works printed but not linked: 3
- Willms, 1994, Inhibition of gastric emptying by glucagon-like peptide (7-36) amide in patients with type-2 diabetes mellitus., Diabetologia, 37, A118
- Knop, 2009, Glucagon responses to increasing oral loads of glucose and corresponding isoglycemic intravenous glucose infusions in patients with type 2 diabetes and healthy subjects., Diabetes, 58, A368
- Knop, 2008, Redcuced incretin effect in obese subjects with normal glucose tolerance as compared to lean control subjects., Diabetes, 57, A410
Cited by
Items 201–217 of 217
Svane, M. S., HINDSØ, M. G., Martinussen, C., Dirksen, C., Jørgensen, N. B., Hedbäck, N., Hartmann, B., Kristiansen, V. B., Holst, J. J., Bojsen-Møller, K. N., et al. (2025) · Diabetes · doi:10.2337/db24-1054 · Cited by 1
Effects of Different Immunosuppressive Drugs on Incretins in Renal Transplant Patients
Yılmaz, N., Sarı, R., Süleymanlar, G., & Özdem, S. (2020) · Journal of the National Medical Association · doi:10.1016/j.jnma.2020.03.012 · Cited by 2
Traitement du diabète de type 2 : l’exénatide, en alternative ou en association à l’insuline ?
Guerci, B., & Sauvanet, J.-P. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70536-4
POUR LE DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE
Sabatier, P., Médecine, F. D., Clinique, M. S., & Bally, É. (2013)
Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients
Røge, R. M. (2016) · Uppsala University Publications (Uppsala University)
Incretin hormones as a target for therapy
Holst, J. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_2
Marathe, C. S. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
The Effect of Micro Element Levels in Drinking Water on Adolescent Body Composition
Çetin, İ., Nazik, A., Nalbantçılar, M. T., & Tosun, K. (2017) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2017.13471
Use of a Nebulizer to Deliver High Frequency High Flow with a Nasal Cannula
Goldstein, M. (2017) · Academic Journal of Pediatrics & Neonatology · doi:10.19080/ajpn.2017.02.555619
Quast, D. R., & Nauck, M. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0268-9 · Cited by 1
Pre-diabetes: Diagnostic Criteria And Therapeutic Approach
Chowdhury, S. R. (2019) · Journal of Chittagong Medical College Teachers Association · doi:10.3329/jcmcta.v29i2.62537
Amoah, I., Cobbinah, J. C., Tawiah, P., Lim, J. J., Yeboah, J. A., & Rush, E. C. (2025) · Cogent Food & Agriculture · doi:10.1080/23311932.2025.2550070
Harnessing Secretin: A Systematic Review of its Emerging Role in Metabolic and Reproductive Health
Mahawar, N., Saxena, G., Srivastava, A. K., Chhabra, B., & Chitme, H. R. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00386-0
Meeks, K. A. C., Bentley, A. R., Assimes, T. L., Franceschini, N., Adeyemo, A., Rotimi, C. N., & Doumatey, A. P. (2023) · Figshare · doi:10.6084/m9.figshare.24741958
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
Signalling and Regulation of the Glucagon-like Peptide-1 receptor
Lu, J. N. (2014) · Figshare
Metadata
- Authors
- Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T.
- Affiliations
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
- University of Copenhagen (DK)
- Corresponding author
- Vilsbøll, Tina
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-03-01
- Volume
- 96
- Issue
- 3
- Pages
- 737-745
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2041551639
- Cited by
- 219
- References
- 33
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 14 · 2023: 15 · 2022: 8 · 2021: 14 · 2020: 15 · 2019: 18 · 2018: 11 · 2017: 14 · 2016: 25 · 2015: 17 · 2014: 14 · 2013: 23 · 2012: 10
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- incretin effect, type 2 diabetes, oral glucose tolerance test, glucose load, glycemic excursions, gastric emptying, glucose homeostasis
- MeSH terms
- Insulin Secretion, Acetaminophen, Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Analgesics, Non-Narcotic, Area Under Curve, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.